Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease

• Status: Terminated
• Trial end date: 2013-04-03
• Target enrollment: 0
• Participant gender: All

Summary

Propanolol is a beta blocker which has been found to inhibit the ability of epinephrine to upregulate sickle red cell adhesion to laminin and endothelial cells in vitro. The purpose of this pilot study is to administer one dose of propanolol to children with sickle cell disease and to measure pre and post dose red cell adhesion. The hypothesis is that a single dose of propanolol will decrease red cell adhesion to laminin and endothelial cells as compared to baseline.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Miami
• Collaborator: Duke University
• Treatments: Propranolol

Criteria

Inclusion Criteria:

1. diagnosis of HbSS or HbSBeta0Thal

2. age 10-17 years

3. Weight 30kg or greater

4. Hb 7mg/dL or greater

5. informed consent

Exclusion Criteria:

1. History of vaso-occlusive crisis during the past 6 weeks, or history of transfusion during the past 3 months.

2. pregnancy

3. history of heart failure, myocardial infarction, asthma, bradyarrythmias, hypotension, thyroid disease, diabetes, renal insufficiency

4. concurrent medications: any antihypertensive medication, diuretics, thyroid replacement medications, any arrythmia medication, insulin, hypoglycaemic medication

5. history of allergy to sulfonamides

6. elevated BUN or creatinine